All articles by GlobalData 

  1. Landmark study shows pharma worse than the automotive industry for carbon emissions

    A study published in the Journal of Cleaner Production has found the global pharma industry to be a major polluter,…
    Read More…

    6 Jun
  2. Amgen unveils promising data in KRAS G12C non-small cell lung cancer

    Amgen’s KRAS G12C inhibitor, AMG 510 has been one of the most closely watched early-phase oncology assets recently. KRAS is…
    Read More…

    6 Jun
  3. Novel biologics are on the horizon for EGFR-mutated non-small cell lung cancer

    One of the highlights of this year’s American Society of Clinical Oncology (ASCO) meeting was the emerging treatment options in…
    Read More…

    6 Jun
  4. AbbVie shoots for AAN 2020 target readout for Phase II MS trials at current enrolment rate

    AbbVie’s Phase II trials of ABT-555 (elezanumab) in various forms of multiple sclerosis (MS) has a target readout at next…
    Read More…

    6 Jun
  5. Novartis denies physicians’ reports of Mayzent launch delays

    Novartis has denied reports that the launch of Mayzent (siponimod), following its 27 March US approval in multiple sclerosis (MS)…
    Read More…

    6 Jun
  6. Long-awaited novel therapies for ovarian cancer have arrived

    Until the last decade, the treatment options for ovarian cancer have remained largely unchanged. The approval of Genentech’s Avastin (bevacizumab),…
    Read More…

    5 Jun
  7. 2018 global prescription drug sales fall against Q4 forecasts

    Globally prescribed drug sales in 2018 failed to reach their Q4 sales forecasts. The top 20 pharmaceutical companies showed an…
    Read More…

    16 May
  8. NIH proposes first guidance for Alzheimer’s-like brain disorder

    The US National Institutes of Health (NIH) recently proposed the first guidance to recognise a brain disorder that mimics Alzheimer’s…
    Read More…

    15 May
  9. Roche’s Phase III DME trials to complete enrolment in 4–5 months

    Roche’s RG7716 (faricimab) is expected to fully enrol its two 900-patient Phase III trials in diabetic macular edema (DME) in…
    Read More…

    15 May
  10. US has lowest diagnosis rate for rheumatoid arthritis compared with other major markets

    Rheumatoid arthritis (RA) is a chronic condition that is a result of an autoimmune disorder. Although it can occur at…
    Read More…

    15 May
Close
Close
Close

Go Top